研究者業績
基本情報
研究分野
1論文
268MISC
330-
日本外科学会定期学術集会抄録集 118回 1088-1088 2018年4月
-
Japanese Journal of Cancer and Chemotherapy 45(4) 649-651 2018年4月1日© 2018 Japanese Journal of Cancer and Chemotherapy Publishers Inc. All rights reserved. Chemotherapy with TAS-102 with bevacizumab (Bmab) is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography (CT) after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.